Meeting
2022 ASCO Annual Meeting
First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.
Authors
Einat Shacham Shmueli
Cancer center, The Chaim Sheba Medical Center, Ramat Gan, Affiliated with the Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel
Einat Shacham Shmueli , Morteza Raeisi , Benoist Chibaudel , Timothy S. Maughan , Jean-Yves Douillard , Eric Van Cutsem , Carsten Bokemeyer , Axel Grothey , Richard Adams , John Raymond Zalcberg , Takayuki Yoshino , Jean-Baptiste Bachet , Romain Cohen , Lama Sharara , Thierry Andre , Qian Shi , Aimery De Gramont
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3578)
DOI
10.1200/JCO.2022.40.16_suppl.3578
Abstract #
3578
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2011 Gastrointestinal Cancers Symposium
Outcome according to metastatic site in patients with KRAS wild-type tumors: Analysis from the CRYSTAL and OPUS studies.
First Author: Eric Van Cutsem
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Bevacizumab in first-line therapy in lung metastases of colorectal cancer: An ARCAD pooled analysis.
First Author: Einat S Shmueli
Poster
2018 Gastrointestinal Cancers Symposium
Prognostic and predictive factors in metastasic colorectal cancer.
First Author: Pilar Garcia Alfonso
Poster
2014 ASCO Annual Meeting
Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.
First Author: Dominik Paul Modest